Seroatlas · Human Serome Atlas

VEGFD

Vascular endothelial growth factor D

Also known as: FIGF, VEGF-D, VEGFD_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O43915
Gene
VEGFD
Ensembl
ENSG00000165197
Chromosome
X
Canonical length
354 aa
Protein class
Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins
Secretome location
Secreted to blood
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C. Read-through transcription has been observed between this locus and the upstream PIR (GeneID 8544) locus. [provided by RefSeq, Feb 2011]

Canonical amino-acid sequenceUniProt

354 residues, UniProt reviewed canonical sequence.

>O43915|VEGFD
     1  MYREWVVVNV FMMLYVQLVQ GSSNEHGPVK RSSQSTLERS EQQIRAASSL EELLRITHSE
    61  DWKLWRCRLR LKSFTSMDSR SASHRSTRFA ATFYDIETLK VIDEEWQRTQ CSPRETCVEV
   121  ASELGKSTNT FFKPPCVNVF RCGGCCNEES LICMNTSTSY ISKQLFEISV PLTSVPELVP
   181  VKVANHTGCK CLPTAPRHPY SIIRRSIQIP EEDRCSHSKK LCPIDMLWDS NKCKCVLQEE
   241  NPLAGTEDHS HLQEPALCGP HMMFDEDRCE CVCKTPCPKD LIQHPKNCSC FECKESLETC
   301  CQKHKLFHPD TCSCEDRCPF HTRPCASGKT ACAKHCRFPK EKRAAQGPHS RKNP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VEGFD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.46
Highest tissue expression
40 nTPM

Expression across tissuesHPA

Tissue

  • lung: 40 nTPM
  • tongue: 22 nTPM
  • breast: 19 nTPM
  • skeletal muscle: 17 nTPM
  • heart muscle: 15 nTPM
  • adipose tissue: 11 nTPM

Single-cell type

  • myonuclei: 103 nCPM
  • fibroblasts: 67 nCPM
  • fibro-adipogenic progenitors: 28 nCPM
  • other brain neurons: 22 nCPM
  • retinal ganglion cells: 19 nCPM
  • brain inhibitory neurons: 17 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • hypothalamus: 3 nTPM
  • pons: 2.9 nTPM
  • cerebral cortex: 2.8 nTPM
  • white matter: 2.7 nTPM
  • basal ganglia: 2.4 nTPM
  • thalamus: 2.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.15
gnomAD pLI
0
DepMap mean gene effect
0.06
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of VEGFD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VEGFD as an antibody target. Whether an autoantibody or antibody against VEGFD could matter depends on whether native VEGFD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VEGFD is annotated as secreted, so native VEGFD circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label VEGFD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/VEGFD. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...